202 related articles for article (PubMed ID: 30986523)
1. Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β-lactamase-producing Enterobacteriaceae infections.
Tacconelli E; Cataldo MA; Mutters NT; Carrara E; Bartoloni A; Raglio A; Cauda R; Mantengoli E; Luzzaro F; Pan A; Beccara LA; Pecile P; Tinelli M; Rossolini GM
Int J Antimicrob Agents; 2019 Jul; 54(1):49-54. PubMed ID: 30986523
[TBL] [Abstract][Full Text] [Related]
2. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
[TBL] [Abstract][Full Text] [Related]
3. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
Sfeir MM; Askin G; Christos P
Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
[TBL] [Abstract][Full Text] [Related]
4. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
[TBL] [Abstract][Full Text] [Related]
5. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
Russo A; Falcone M; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale PL; Oliver A; Ruiz-Garbajosa P; Gasch O; Gozalo M; Pitout J; Akova M; Peña C; Cisneros JM; Hernández-Torres A; Farcomeni A; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Karaiskos I; de la Calle C; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Rodriguez-Gomez J; Souli M; Bonomo RA; Paterson DL; Carmeli Y; Pascual A; Rodríguez-Baño J; Venditti M;
Int J Antimicrob Agents; 2018 Nov; 52(5):577-585. PubMed ID: 29969692
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes and prognostic factors in bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae among patients with malignancy: a meta-analysis.
Jiang AM; Liu N; Zhao R; Zheng HR; Chen X; Fan CX; Zhang R; Zheng XQ; Fu X; Yao Y; Tian T
Ann Clin Microbiol Antimicrob; 2020 Nov; 19(1):53. PubMed ID: 33228668
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and Burden of Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae in a Pediatric Hospital in Senegal.
Ndir A; Diop A; Faye PM; Cissé MF; Ndoye B; Astagneau P
PLoS One; 2016; 11(2):e0143729. PubMed ID: 26867226
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae blood isolates with inducible AmpC β-lactamase.
Cheong HS; Ko KS; Kang CI; Chung DR; Peck KR; Song JH
Microb Drug Resist; 2012 Aug; 18(4):446-52. PubMed ID: 22409779
[TBL] [Abstract][Full Text] [Related]
9. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
[TBL] [Abstract][Full Text] [Related]
10. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
[TBL] [Abstract][Full Text] [Related]
11. Nosocomial acquisition of methicillin-resistant Staphyloccocus aureus (MRSA) and extended-spectrum beta-lactamase (ESBL) Enterobacteriaceae in hospitalised patients: a prospective multicenter study.
De Angelis G; Restuccia G; Venturiello S; Cauda R; Malhotra-Kumar S; Goossens H; Schrenzel J; Tacconelli E
BMC Infect Dis; 2012 Mar; 12():74. PubMed ID: 22458427
[TBL] [Abstract][Full Text] [Related]
12. Use of non-carbapenem antibiotics to treat severe extended-spectrum β-lactamase-producing Enterobacteriaceae infections in intensive care unit patients.
Luyt CE; Faure M; Bonnet I; Besset S; Huang F; Junot H; Hékimian G; Schmidt M; Bréchot N; Combes A; Aubry A; Mayaux J; Chastre J
Int J Antimicrob Agents; 2019 May; 53(5):547-552. PubMed ID: 30742956
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae.
Nakai H; Hagihara M; Kato H; Hirai J; Nishiyama N; Koizumi Y; Sakanashi D; Suematsu H; Yamagishi Y; Mikamo H
J Infect Chemother; 2016 May; 22(5):319-26. PubMed ID: 26968486
[TBL] [Abstract][Full Text] [Related]
14. Predominance of healthcare-associated cases among episodes of community-onset bacteraemia due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
Zahar JR; Lesprit P; Ruckly S; Eden A; Hikombo H; Bernard L; Harbarth S; Timsit JF; Brun-Buisson C;
Int J Antimicrob Agents; 2017 Jan; 49(1):67-73. PubMed ID: 27890442
[TBL] [Abstract][Full Text] [Related]
15. Clinical profiles of patients colonized or infected with extended-spectrum beta-lactamase producing Enterobacteriaceae isolates: a 20 month retrospective study at a Belgian University Hospital.
Schoevaerdts D; Bogaerts P; Grimmelprez A; de Saint-Hubert M; Delaere B; Jamart J; Swine C; Glupczynski Y
BMC Infect Dis; 2011 Jan; 11():12. PubMed ID: 21226923
[TBL] [Abstract][Full Text] [Related]
16. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis.
Vardakas KZ; Tansarli GS; Rafailidis PI; Falagas ME
J Antimicrob Chemother; 2012 Dec; 67(12):2793-803. PubMed ID: 22915465
[TBL] [Abstract][Full Text] [Related]
17. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
[TBL] [Abstract][Full Text] [Related]
18. Microbiological screening is necessary to distinguish carriers of plasmid-mediated AmpC beta-lactamase-producing enterobacteriaceae and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae because of clinical similarity.
Conen A; Frei R; Adler H; Dangel M; Fux CA; Widmer AF
PLoS One; 2015; 10(3):e0120688. PubMed ID: 25803720
[TBL] [Abstract][Full Text] [Related]
19. Detecting risk and predicting patient mortality in patients with extended-spectrum β-lactamase-producing Enterobacteriaceae bloodstream infections.
Trecarichi EM; Cauda R; Tumbarello M
Future Microbiol; 2012 Oct; 7(10):1173-89. PubMed ID: 23030423
[TBL] [Abstract][Full Text] [Related]
20. Mortality impact of empirical antimicrobial therapy in ESBL- and AmpC-producing Enterobacteriaceae bacteremia in an Australian tertiary hospital.
Lim CL; Spelman D
Infect Dis Health; 2019 Aug; 24(3):124-133. PubMed ID: 30928569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
